A new linear glyceryl acid derived heptapeptide (1), together with known isocoumarin antibiotic, Y-05460M-A (2), were isolated from the culture of the deep sea sediment strain Sl 79 classified as “Paenibacillus profundus” sp. nov. Their structures were determined by 1D- and 2D- NMR techniques and ESI-MS/MS experiments. HPLC analysis of the Marfey derivatives in comparison to their analogs of authentic amino acids revealed that all amino acids in peptide 1, with an exception of Val, have the D-configuration. The compound 1 showed inhibitory activity against Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Enterococcus faecium as well as cytotoxic and moderate colony growth inhibitory activity against SK-MEL-28 cell line.
RomanenkoL.A., TanakaN., SvetashevV.I., KalinovskayaN.I. (2012) Paenibacillus profundus sp. nov., a deep sediment bacterium that produces isocoumarin and peptide antibiotics. Archives of Microbiology, in press.
2.
(a) SahaP., MondalA.K., MayilrajS., KrishnamurthiS., BhattacharyaA., ChakrabartiT. (2005) Paenibacillus assamensis sp. nov., a novel bacterium isolated from a warm spring in Assam, India. International Journal of Systematic and Evolutionary Microbiology, 55, 2577–2581; (b) Li J, Beatty PK, Shah S, Jensen SE. (2007) Use of PCR-targeted mutagenesis to disrupt production of fusaricidin-type antifungal antibiotics in Paenibacillus polymyxa. Applied and Environmental Microbiology, 73, 3480-3489.
3.
(a) ItoM., KoyamaY. (1972) Jolipeptin, a new peptide antibiotic. Isolation, physicochemical and biological characteristics. Journal of Antibiotics, 25, 304–308; (b) Katz E, Demain AL. (1977) The peptide antibiotics of Bacillus: chemistry, biogenesis and possible role. Bacteriological Review, 41, 449-475; (c) Shoji J, Kato T, Hinoo H. (1977) The structure of polymyxin T. Journal of Antibiotics, 30, 1042-1048; (d) Horton J, Pankey GA. (1982) Polymyxin B, colistin, and sodium colistimethate. Medical Clinics of North America, 66, 135-142; (e) Pichard B, Larue JP, Thouvenot D. (1995) Gavaserin and saltavalin, new peptide antibiotics produced by Bacillus polymyxa. FEMS Microbiology Letters, 133, 215-218; (f) Donald KMD. (2004) Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infectious Disease Clinics of North America, 18, 669-689.
4.
(a) NakajimaN., ChiharaS., KoyamaY. (1972) A new antibiotic, gatavalin I. Isolation and characterization. Journal of Antibiotics, 25, 243–247; (b) Kurusu K, Ohba K. (1987) New peptide antibiotics LI-F03, F04, F05, F07, and F08, produced by Bacillus polymyxa I. Isolation and characterization. Journal of Antibiotics, 40, 1506-1514; (c) Kajimura Y, Kaneda M. (1996) Fusaricidin A, a new depsipeptide antibiotic produced by Bacillus polymyxa KT-8, taxonomy, fermentation, isolation, structure elucidation and biological activity. Journal of Antibiotics.49, 129-135; (d) Kajimura Y, Kaneda M. (1997) Fusaricidin B, C and D, new depsipeptide antibiotics produced by Bacillus polymyxa KT-8, isolation, structure elucidation and biological activity. Journal of Antibiotics, 50, 220-228; (e) Beatty PH, Jensen SE. (2002) Paenibacillus polymyxa produces fusaricidin-type antifungal antibiotics active against Leptosphaeria maculans, the causative agent of blackleg disease of canola. Canadian Journal of Microbiology, 48, 159-169; (f) Teesch LM, Adams J. (1991) Fragmentations of gas-phase complexes between alkali metal ions and peptides: metal ion binding to carbonyl oxygens and other neutral functional groups. Journal of the American Chemical Society, 113, 812-820; (g) Marfey P. (1984) Determination of D-amino acids. II. Use of a bifunctional reagent, 1,5-difluoro-2,4-dinitrobenzene. Carlsberg Research Communications, 49, 591-596.
5.
OkazakiH., KishiT., BeppuT., ArimaK. (1975) A new antibiotic, baciphelacin. Journal of Antibiotics, 28, 717–719.
6.
ItohJ., ShomuraT., OmotoS., MiyadoS., YudaY., ShibataU., InouyeS. (1982) Isolation, physicochemical properties and biological activities of amicoumacins produced by Bacillus pumilus.Agricultural Biology and Chemistry, 46, 1255–1259.
7.
(a) CanedoL.M., Fernandez PuentesJ.L., Perez BazJ., AcebalC., de la CalleF., Garcia GravalosD., Garcia de QuesadaT. (1997) PM-94128, a new isocoumarin antitumor agent produced by a marine bacterium. Journal of Antibiotics, 50, 175–176; (b) Huang Y-F, Li L-H, Tian L, Qiao L, Hua H-M, Pei Y-H. (2006) Sg17-1–4, a novel isocoumarin from a marine fungus Alternaria tenuis Sg17-1. Journal of Antibiotics, 59, 355-357; (c) Itoh J, Omoto S, Shomura T, Nishizawa N, Miyado S, Yuda Y, Shibata U, Inouye S. (1981) Amicoumacin-A, a new antibiotic with strong anti-inflammatory and antiulcer activity. Journal of Antibiotics, 34, 611-613.
8.
(a) McInerneyB.V., TaylorW.C., LaceyM.J., AkhurstR.J., GregsonR.P. (1991) Biologically active metabolites from Xenorhabdus spp., Part 2. Benzopyran-1-one derivatives with gastroprotective activity. Journal of Natural Products, 54, 785–795; (b) Sato T, Nagai K, Suzuki K, Morioka M, Saito T. (1992) A new isocoumarin antibiotic, Y-05460M-A. Journal of Antibiotics, 45, 1949-1952.
9.
KalinovskayaN., KalinovskyA., RomanenkoL., PushilinM., DmitrenokP., KuznetsovaT. (2008) New Angucyclinones from the Marine Mollusk Associated Actinomycete Saccharothrix espanaensis An 113. Natural Product Communications, 3, 1611–1616.
10.
BarltropJ.A., OwenT.C., CoryA.H., CoryJ.G. (1991) 5-(3-carboxymethoxyphenyl)–2-(4,5- dimethylthiazolyl)–3-(4-sulfophenyl) tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)–2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell-viability indicators. Bioorganic Medicinal Chemistry Letters, 1, 611–614.
11.
DyshlovoyS.A., FedorovS.N., KalinovskyA.I., ShubinaL.K., BokemeyerC., StonikV.A., HoneckerF. (2012) Mycalamide A Shows Cytotoxic Properties and Prevents EGF- Induced Neoplastic Transformation through Inhibition of Nuclear Factors. Marine Drugs, 10, 1212–1224.
